Abstract
Psoriasis is an immune-mediated, chronic, inflammatory disease that affects the skin and joints. Because of its high incidence and of its clinical symptoms it has a very strong social impact. In a genetically predisposed individual, the maintenance of the skin barrier integrity is strongly compromised in response to either environmental or self-antigenic insults. A persistent dysregulation of the skin immune system causes the typical evolutive skin lesions of psoriasis and recurrence of the disease. The most efficient laboratory approach consists of a well-defined evaluation of immune response in order to help diagnosis, to monitor evolution, and to evaluate the effects of individualized therapeutic treatments.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496–509.10.1056/NEJMra0804595Search in Google Scholar PubMed
2. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol 2007;25:535–46.10.1016/j.clindermatol.2007.08.007Search in Google Scholar PubMed
3. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64(Suppl 2):ii18–23.10.1136/ard.2004.033217Search in Google Scholar PubMed PubMed Central
4. Scarpa R. New insights into the concept of psoriatic disease. J Rheumatol Suppl 2012;89:4–6.10.3899/jrheum.120231Search in Google Scholar PubMed
5. Raychaudhuri SP. A cutting edge overview: psoriatic disease. Clin Rev Allergy Immunol 2013. Available from: http://dx.doi.org/10.1007/s12016-012-8309-z. 10.1007/s12016-012-8309-zSearch in Google Scholar PubMed
6. Taylor WJ. Impact of psoriatic arthritis on the patient: through the lens of the WHO International Classification of Functioning, Health, and Disability. Curr Rheumatol Rep 2012;14:369–74.10.1007/s11926-012-0263-5Search in Google Scholar PubMed
7. Campalani E, Baker JN. The clinical genetics of psoriasis. Curr Genomics 2005;6:51–60.10.2174/1389202053202157Search in Google Scholar
8. Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T, etal. Molecular dissection of psoriasis: integrating genetics and biology. J Invest Dermatol 2010;130:1213–26.10.1038/jid.2009.319Search in Google Scholar PubMed
9. Capon F, Barker JN. The quest for psoriasis susceptibility genes in the postgenome-wide association studies era: charting the road ahead. Br J Dermatol 2012;166:1173–5.10.1111/j.1365-2133.2012.10895.xSearch in Google Scholar PubMed
10. Henseler T. Genetics of psoriasis. Arch Dermatol Res 1998;290:463–76.10.1007/s004030050338Search in Google Scholar PubMed
11. Zhang X. Genome-wide association study of skin complex diseases. J Dermatol Sci 2012;66:89–97.10.1016/j.jdermsci.2012.02.017Search in Google Scholar
12. Armstrong AW, Schupp C, Bebo B. Psoriasis comorbidities: results from the National Psoriasis Foundation Surveys 2003 to 2011. Dermatology 2012;225:121–5.10.1159/000342180Search in Google Scholar
13. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. Arch Dermatol 2012;15:1–8.Search in Google Scholar
14. Gelfand JM, Yeung H. Metabolic syndrome in patients with psoriatic disease. J Rheumatol Suppl 2012;89:24–8.10.3899/jrheum.120237Search in Google Scholar
15. Love TJ, Qureshi AA, Wood Karlson E, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis. Results from the National Health and Nutrition Examination Survey, 2003–2006. Arch Dermatol 2011;147:419–24.10.1001/archdermatol.2010.370Search in Google Scholar
16. Manolache L, Peluscu-Seceleanu D, Benea V. Life events involvement in psoriasis onset/recurrence. Int J Dermatol 2010;49:636–41.10.1111/j.1365-4632.2009.04367.xSearch in Google Scholar
17. Higgins E. Alcohol, smoking and psoriasis. Clin Exp Dermatol 2000;25:107–10.10.1046/j.1365-2230.2000.00588.xSearch in Google Scholar
18. Abel EA, Di Cicco LM, Orenberg EK, Fraki JE, Farber EM. Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986;15:1007–12.10.1016/S0190-9622(86)70265-XSearch in Google Scholar
19. Wolff R, Ruocco V. Triggered psoriasis. Adv Exp Med Biol 1999;455:221–5.10.1007/978-1-4615-4857-7_32Search in Google Scholar PubMed
20. Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol Mech Dis 2012;7:385–422.10.1146/annurev-pathol-011811-132448Search in Google Scholar PubMed
21. Sabat R, Philipp S, Höflich C, Kreutzer S, Wallace E, Asadullah K, etal. Immunopathogenesis of psoriasis. Exp Dermatol 2007;16:779–98.10.1111/j.1600-0625.2007.00629.xSearch in Google Scholar PubMed
22. Boulinguez S. Current topics in psoriasis. Ann Dermatol Venereol 2011;138(Suppl 1):H1–5.10.1016/S0151-9638(11)70060-6Search in Google Scholar
23. Nograles KE, Davidovici B, Krueger JG. New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg 2010;29:3–9.10.1016/j.sder.2010.03.001Search in Google Scholar PubMed PubMed Central
24. Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005;5: 699–711.10.1038/nri1689Search in Google Scholar PubMed
25. Balato A, Unutmaz D, Gaspari AA. Natural killer T cells: an unconventional T-cell subset with diverse effector and regulatory functions. J Invest Dermatol 2009;129:1628–42.10.1038/jid.2009.30Search in Google Scholar PubMed
26. Liew SC, Das-Gupta E, Chakravarthi S, Wong SF, Lee N, Safdar N, etal. Differential expression of the angiogenesis growth factors in psoriasis vulgaris. Res Notes 2012;5:201.10.1186/1756-0500-5-201Search in Google Scholar PubMed PubMed Central
27. Zaba LC, Krueger JG, Lowes MA. Resident and “inflammatory” dendritic cells in human skin. J Invest Dermatol 2009;129:302–8.10.1038/jid.2008.225Search in Google Scholar PubMed PubMed Central
28. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, Abello MV, Novitskaya I, Pierson KC, etal. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 2009;129:79–88.10.1038/jid.2008.194Search in Google Scholar PubMed PubMed Central
29. Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, etal. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009;30:576–87.10.1016/j.immuni.2009.02.007Search in Google Scholar PubMed PubMed Central
30. Johnston A, Xing X, Guzman AM, Riblett M, Loyd CM, Ward NL, etal. IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol 2011;186:2613–22.10.4049/jimmunol.1003162Search in Google Scholar PubMed PubMed Central
31. Di Meglio P, Nestle FO. The role of IL-23 in the immunopathogenesis of psoriasis. F1000 Biol Rep 2010;2:pii40.10.3410/B2-40Search in Google Scholar PubMed PubMed Central
32. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009;129:1339–50.10.1038/jid.2009.59Search in Google Scholar PubMed
33. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010;130:1373–83.10.1038/jid.2009.399Search in Google Scholar PubMed PubMed Central
34. Tokura Y, Mori T, Hino R. Psoriasis and other Th17 mediated skin diseases. J UOEH 2010;32:317–28.10.7888/juoeh.32.317Search in Google Scholar PubMed
35. Enerbaeck C. Soluble biomarkers in psoriasis. Eur J Dermatol 2011;21:844–50.10.1684/ejd.2011.1482Search in Google Scholar PubMed
36. Rashmi R, Rao KS, Basavaraj KH. A comprehensive review of biomarkers in psoriasis. Clin Exp Dermatol 2009;34:658–63.10.1111/j.1365-2230.2009.03410.xSearch in Google Scholar PubMed
37. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004;150:917–28.10.1111/j.1365-2133.2004.05984.xSearch in Google Scholar PubMed
38. Kallimanis PG, Xenos K, Markantonis SL, Stavropoulos P, Margaroni G, Katsambas A, etal. Serum levels of transforming growth factor-beta 1 in patients with mild psoriasis vulgaris and effect of treatment with biological drugs. Clin Exp Dermatol 2009;34:582–6.10.1111/j.1365-2230.2008.03026.xSearch in Google Scholar PubMed
39. Flisiak I, Zaniewski P, Chodynicka B. Plasma TGF-beta 1, TIMP-1, MMP-1 and IL-8 as a combined biomarker of psoriasis activity. Biomarkers 2008;13:549–56.10.1080/13547500802033300Search in Google Scholar PubMed
40. Anderson KS, Petersson S, Wong J, Shubbar E, Lokko NN, Carlstroem M, etal. Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris. Br J Dermatol 2010;163:1085–9.10.1111/j.1365-2133.2010.09990.xSearch in Google Scholar PubMed
41. Anderson KS, Wong J, Polyak K, Aronzon D, Enerbaeck C. Detection of psoriasin/S100A7 in the sera of patients with psoriasis. Br J Dermatol 2009;160:325–32.10.1111/j.1365-2133.2008.08904.xSearch in Google Scholar PubMed
42. Benoit S, Toksoy A, Ahlmann M, Schmidt M, Sunderkoetter C, Foell D, etal. Elevated serum levels of calcium-binding S100 proteins A8 and A9 reflect disease activity and abnormal differentiation of keratinocytes in psoriasis. Br J Dermatol 2006;155:62–6.10.1111/j.1365-2133.2006.07198.xSearch in Google Scholar
43. Ritchlin CT, Qureshi AA, de Vlam K, Pitzalis C, Helliwell PS, Mease PJ, etal. Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008. J Rheumatol 2010;37:462–7.10.3899/jrheum.090957Search in Google Scholar
44. Chadran V, Cook RJ, Edwin J, Shen H, Pellett FJ, Shanmugarajah S, etal. Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology 2010;49:1399–405.10.1093/rheumatology/keq105Search in Google Scholar
45. Chen YJ, Wu CY, Shen JL, Chu SY, Chen CK, Chang YT, etal. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008;144:1571–5.10.1001/archderm.144.12.1571Search in Google Scholar
46. Johnston A, Arnadottir S, Gudjonsson JE, Aphale A, Sigmarsdottir AA, Gunnarsson SI, etal. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol 2008;159:342–50.10.1111/j.1365-2133.2008.08655.xSearch in Google Scholar
47. Malerba M, Gisondi P, Radaeli A, Sala R, Calzavara Pinton PG, Girolomoni G. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 2006;155:1165–9.10.1111/j.1365-2133.2006.07503.xSearch in Google Scholar
48. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintaqnilha A. Dyslipidemia and oxidative stress in mild and severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001;303:33–9.10.1016/S0009-8981(00)00358-2Search in Google Scholar
49. Gulletta E. Citochine: caratteristiche biologiche. In: Gulletta E, Foti DP, Galliera E, Corsi MM, editors. Citochine e chemochine. Caleidoscopio. Genova: Medical Systems, 2008:1–26.Search in Google Scholar
50. Scarmozzino MG, Tassone MC, Accattato F, Greco M, Ventura V, Foti DP. Cytometric bead assay (Cba) e microarray: confronto tra due nuove metodologie per il dosaggio di citochine. Il Patol Clin 2009;42:6–9.Search in Google Scholar
51. Buckner JH. Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010;10:849–59.10.1038/nri2889Search in Google Scholar PubMed PubMed Central
52. Castela E, Archier E, Devaux S, Gallini A, Aractingi S, Cribier B, etal. Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities. J Eur Acad Dermatol Venereol 2012;3:36–46.10.1111/j.1468-3083.2012.04522.xSearch in Google Scholar PubMed
53. Bailey EE, Ference EH, Alikhan A, Hession MT, Armstrong AW. Combination treatments for psoriasis: a systematic review and meta-analysis. Arch Dermatol 2012;148:511–22.10.1001/archdermatol.2011.1916Search in Google Scholar PubMed
54. Rahman M, Zaki Ahmad M, Kazmi I, Akhter S, Beg S, Gupta G, etal. Insight into the biomarkers as the novel anti-psoriatic drug discovery tool: a contemporary viewpoint. Curr Drug Discov Technol 2012;9:48–62.10.2174/157016312799304516Search in Google Scholar PubMed
55. Tang C, Chen S, Qian H, Huang W. Interleukin-23: as a drug target for autoimmune inflammatory disease. Immunology 2012;135:112–24.10.1111/j.1365-2567.2011.03522.xSearch in Google Scholar PubMed PubMed Central
56. Toussirot E. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets 2012;11:159–68.10.2174/187152812800392805Search in Google Scholar PubMed
57. Kurzeja M, Rudnicka L, Olszewska M. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. Am J Clin Dermatol 2011;12:113–25.10.2165/11538950-000000000-00000Search in Google Scholar PubMed
58. Hueber W, Patel DD, Dryia T, Wright AM, Koroleva I, Bruin G, etal. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2:52ra72.10.1126/scitranslmed.3001107Search in Google Scholar PubMed
59. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, etal. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366:1190–9.10.1056/NEJMoa1109997Search in Google Scholar PubMed
©2013 by Walter de Gruyter Berlin Boston
